Explore every episode of the podcast The Lancet Oncology in conversation with
| Title | Pub. Date | Duration | |
|---|---|---|---|
| James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study | 30 mars 2026 | 00:10:02 | |
Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE). Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00762-4/fulltext Tell us what you thought about this episode Continue this conversation on social! | |||
| Ali Landman on the European Congress of Radiology 2026 | 17 mars 2026 | 00:14:07 | |
Join us for this special episode where Deputy Editor Cheryl Lai speaks with Ali Landman, Editor-in-Chief of The Lancet Medical Imaging & Theranostics, about the scope and vision of the new journal and Ali's highlights in oncological imaging from the European Congress of Radiology in Vienna, March 4-8, 2026. To submit your manuscript: https://www2.cloud.editorialmanager.com/thelancetimaging/default2.aspx Tell us what you thought about this episode Continue this conversation on social! | |||
| Kayleigh Bhangdia on breast cancer GBD study 2023 | 09 mars 2026 | 00:17:30 | |
Kayleigh Bhangdia discusses the latest GBD breast cancer study data, telling the audience about epidemiological trends, disease burden, and risk factors associated with breast cancer globally, regionally, and nationally for 204 countries from 1990 to 2023. Kayleigh sheds light on disparities in breast cancer burden across the globe and forecasts to 2050, and highlights the the most critical areas that future GBD studies should focus on to improve the accuracy, relevance, and impact of breast cancer estimates worldwide. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00730-2/fulltext Tell us what you thought about this episode Continue this conversation on social! | |||
| Dylan Graetz and Erica Kaye on qualitative research in oncology | 02 févr. 2026 | 00:42:06 | |
Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Dylan Graetz (Department of Oncology and Department of Global Pediatric Medicine, St Jude Children’s Research Hospital) and Dr Erica Kaye (Department of Oncology, St Jude Children’s Research Hospital) to discuss qualitative in oncology. and the reviews in Lancet Haematology 2026 https://doi.org/10.1016/S2352-3026(25)00321-7 Tell us what you thought about this episode Continue this conversation on social! | |||
| Jesse Plascak and Marissa Baker on cancer mortality rates by occupation among US workers | 29 déc. 2025 | 00:22:54 | |
Cheryl Lai, Senior Editor of The Lancet Oncology, is joined by Dr Jesse Plascak (Division of Cancer Prevention and Control, The Ohio State University) and Dr Marissa Baker (Department of Environmental & Occupational Health Science, University of Washington School of Public Health) to discuss their population-based study analysing cancer mortality rates by sex, cancer type, and occupation type among working-age adults in the USA. Tell us what you thought about this episode Continue this conversation on social! | |||
| Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3 | 25 nov. 2025 | 00:25:41 | |
Dr Andre Pfob (Department of Obstetrics & Gynecology, Heidelberg University Hospital) and Prof Peter Dubsky (Faculty of Health Sciences and Medicine, University of Lucerne) discuss their Review entitled The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus. Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00463-2/fulltext Tell us what you thought about this episode Continue this conversation on social! | |||
| Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission | 02 nov. 2025 | 00:10:46 | |
Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care. Click here to read the full Commission: The human crisis in cancer: a Lancet Oncology Commission And comment: Re-establishing human-centred care Tell us what you thought about this episode Continue this conversation on social! | |||
| Matthias Preusser on the phase 2 TUXEDO-3 trial | 27 oct. 2025 | 00:17:10 | |
Deputy Editor Ali Landman speaks with Matthias Preusser (Medical University of Vienna, Vienna, Austria) about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer. Hear about the potential of HER3-targeted antibody-drug conjugates for brain metastases, why recruiting patients with active brain metastases to clinical trials is so important, and where the field is going next. Click here to read the full article: Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial Click here to read the full article: Patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial Tell us what you thought about this episode Continue this conversation on social! | |||
| Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer | 29 sept. 2025 | 00:12:15 | |
Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan, Italy, to discuss his SunRISe4-trial published in our October issue. Read the full article: Tell us what you thought about this episode Continue this conversation on social! | |||
| Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas | 02 sept. 2025 | 00:14:22 | |
Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl, from institutions in the USA and Canada, to discuss two exciting papers on TERT expression and TERT promoter mutations in meningiomas. You can read the two Articles here: Tell us what you thought about this episode Continue this conversation on social! | |||
| Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer | 28 juil. 2025 | 00:07:36 | |
Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Dr Jinming Li, from the Department of Colorectal Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China to discuss his international, multicohort, observational study on patterns in genomic mutations among patients with early-onset colorectal cancer. Read the full article: Tell us what you thought about this episode Continue this conversation on social! | |||
| Abdalla Awidi on cancer control in the Middle East | 11 juin 2025 | 00:08:22 | |
Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Professor Abdalla Awidi (Founder and Director of Stem Cell Therapy Center, University of Jordan, Amman, Jordan) to discuss The Lancet Oncology's Cancer control in the Middle East Series. The Series comprises five papers from regional experts who discuss the current outlook for cancer in the Middle East and future developments. See the whole Series here: Watch the Series video here: https://youtu.be/t3AGdouXpqg Tell us what you thought about this episode Continue this conversation on social! | |||
| ASCO 2025 Debrief | 11 juin 2025 | 00:14:45 | |
Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167 Articles discussed in this podcast episode include: Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study: Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial: Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial: #asco2025 Tell us what you thought about this episode Continue this conversation on social! | |||
| Caroline Robert on treatments for patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN trial) | 28 mai 2025 | 00:10:45 | |
Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Professor Caroline Robert from Gustave Roussy Cancer Campus, France to discuss the EBIN trial. EBIN was an open-label, randomised, controlled, phase 2 trial conducted at 37 centres in eight European countries, and aimed to investigate the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors in patients with metastatic melanoma with BRAFV600E or BRAFV600K mutations. They discuss the disease burden of advanced melanoma with BRAF mutations, the key findings from the EBIN trial, and the future implications of the study findings, especially for a select sub-population of patients with advanced melanoma. Read the full article: Tell us what you thought about this episode Continue this conversation on social! | |||
| Richard Bryant on transperineal vs transrectal biopsy for prostate cancer | 30 avr. 2025 | 00:18:02 | |
Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Richard Bryant from the University of Oxford to discuss the TRANSLATE trial. This extensive UK-based randomised controlled trial compares the use of local anaesthetic ultrasound-guided transperineal biopsy with the traditional transrectal biopsy approach for diagnosing prostate cancer. They analyse the key findings of the trial, including the detection rates of clinically significant prostate cancer, infection risks, patient experiences, and the potential implications for clinical practice and health policy. Read the full article: Tell us what you thought about this episode Continue this conversation on social! | |||
| Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA) | 31 mars 2025 | 00:07:33 | |
Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in the MARCAP Consortium. Read the full article: Tell us what you thought about this episode Continue this conversation on social! | |||
| Ariana Znaor on cancer surveillance in the Eastern Mediterranean region | 03 mars 2025 | 00:20:03 | |
Ariana Znaor (Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France) discusses her Review on cancer surveillance in the Eastern Mediterranean Region: a 10-year IARC-WHO EMRO collaboration. Tell us what you thought about this episode Continue this conversation on social! | |||
| Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials | 03 févr. 2025 | 00:18:03 | |
Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 randomised clinical trials. Tell us what you thought about this episode Continue this conversation on social! | |||
| Yannick Romero on the changing landscape of national cancer control plans | 02 janv. 2025 | 00:24:40 | |
Dr Yannick Romero (Union for International Cancer Control) discusses his Policy Review on the changing landscape of the national cancer control plans and his work with the international cancer control partnership. Tell us what you thought about this episode Continue this conversation on social! | |||
| M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries | 02 déc. 2024 | 00:22:15 | |
Professor M Saiful Huq (Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, USA) and Dr Mostafa Aziz Sumon (Radiation Oncology, Kurmitola General Hospital, Dhaka, Bangladesh) discuss their Series on Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries. Tell us what you thought about this episode Continue this conversation on social! | |||
| Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma | 30 oct. 2024 | 00:15:07 | |
Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma. Tell us what you thought about this episode Continue this conversation on social! | |||
| Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination | 30 sept. 2024 | 00:17:21 | |
Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations. Tell us what you thought about this episode Continue this conversation on social! | |||
| May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics | 30 sept. 2024 | 00:40:45 | |
May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics. Tell us what you thought about this episode Continue this conversation on social! | |||
| Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02) | 27 août 2024 | 00:13:22 | |
Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’. Tell us what you thought about this episode Continue this conversation on social! | |||
| Emmy Boerrigter on dose selection of novel anticancer drugs | 29 juil. 2024 | 00:11:41 | |
Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses. Tell us what you thought about this episode Continue this conversation on social! | |||
| Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations | 24 juin 2024 | 00:36:56 | |
Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendations in diagnosis and clinical trial endpoints. Tell us what you thought about this episode Continue this conversation on social! | |||
| Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment | 28 mai 2024 | 00:24:08 | |
Dr Garth Strohbehn (Veteran Affairs Center for Clinical Management Research, Ann Arbor, Michigan, USA) and Dr Katie Lichter (University of California, San Francisco, USA) discuss their papers on the environmental impact of cancer treatments and the public harms resulting from it. Tell us what you thought about this episode Continue this conversation on social! | |||
| James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean | 29 avr. 2024 | 00:35:05 | |
Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American Cancer Society, Georgia, USA) discuss their Personal View entitled, ‘Protecting Caribbean patients diagnosed with cancer from compounding disasters. Tell us what you thought about this episode Continue this conversation on social! | |||
| Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials | 08 avr. 2024 | 00:11:22 | |
Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer. Tell us what you thought about this episode Continue this conversation on social! | |||
| Maria Kyrgiou on innovations in gynaecological cancers and global disparities | 07 mars 2024 | 00:25:42 | |
In a special episode on International Women's Day 2024, we speak with Dr Maria Kyrgiou (Imperial College London, London, UK) about her Essay on innovations and disparities in gynaecological cancer care. Tell us what you thought about this episode Continue this conversation on social! | |||
| Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers | 26 févr. 2024 | 00:34:43 | |
Dr Georgios Lyratzopoulos (University College London, London, UK) discusses his two papers from the International Cancer Benchmarking Partnership on the use of chemotherapy or radiotherapy in eight common cancers in Norway, the UK, Canada, and Australia. Tell us what you thought about this episode Continue this conversation on social! | |||
| Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer | 29 janv. 2024 | 00:16:06 | |
Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.’ Tell us what you thought about this episode Continue this conversation on social! | |||
| Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma | 02 janv. 2024 | 00:13:53 | |
Senior Editor Owen Stretton talks to Professor Shankar Siva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery’s new systematic review and practice guidelines for stereotactic body radiotherapy in primary renal cell carcinoma. Tell us what you thought about this episode Continue this conversation on social! | |||
| Neerja Bhatla on a new quadrivalent HPV vaccine | 29 nov. 2023 | 00:12:24 | |
Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India. Tell us what you thought about this episode Continue this conversation on social! | |||
| Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery | 01 nov. 2023 | 00:43:49 | |
Dr Chandra Are (University of Nebraska Medical Center, Omaha, NE, USA) discusses highlights and recommendations from the Lancet Oncology Commission on Global cancer surgery: pragmatic solutions to improve cancer surgery outcomes worldwide. Tell us what you thought about this episode Continue this conversation on social! | |||
| Philipp Karschnia on tissue sampling and processing during resection of diffuse intracranial glioma | 31 oct. 2023 | 00:17:10 | |
Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium’s recommendations on standardised tissue sampling and processing during resection of diffuse intracranial glioma. Tell us what you thought about this episode Continue this conversation on social! | |||
| Wanda Cui on measuring ovarian toxicity | 03 oct. 2023 | 00:10:37 | |
Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials. Tell us what you thought about this episode Continue this conversation on social! | |||
| Ticiana Leal on Tumour Treating Fields | 01 sept. 2023 | 00:09:01 | |
Ticiana Leal (Winship Cancer Institute at Emory University, Atlanta, GA, USA) discusses her paper on Tumour Treating Fields. Tell us what you thought about this episode Continue this conversation on social! | |||
| Xuesong Han on cancer diagnosis during the COVID-19 pandemic in the USA | 02 août 2023 | 00:12:31 | |
Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA. Tell us what you thought about this episode Continue this conversation on social! | |||
| Carlos Fernández de Larrea and Damian Green on BCMA CAR T cells in multiple myeloma | 03 juil. 2023 | 00:33:50 | |
Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma. Tell us what you thought about this episode Continue this conversation on social! | |||
| Madeline Pe on the SISAQOL initiative | 31 mai 2023 | 00:14:01 | |
Madeline Pe (EORTC, Brussels, Belgium) discusses her Policy Review on the innovative medicines initiative, an expansion of the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials (SISAQOL) initiative. Tell us what you thought about this episode Continue this conversation on social! | |||
| Kadia Petricca and Joyce Kambugu on access to essential cancer medicines for children | 02 mai 2023 | 00:28:40 | |
Dr Kadia Petricca (SickKids Hospital, Toronto, Canada), Dr Joyce Kambugu (Uganda Cancer Institute, Kampala, Uganda), and Dr Avi Denburg (SickKids Hospital) discuss their paper “Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa”. Tell us what you thought about this episode Continue this conversation on social! | |||
| Mark Lythgoe on UK oncology drug approval after Brexit | 27 mars 2023 | 00:14:11 | |
Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit". Tell us what you thought about this episode Continue this conversation on social! | |||
| Janet Brown on the phase 2/3 STAR trial | 28 févr. 2023 | 00:20:43 | |
Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma. Tell us what you thought about this episode Continue this conversation on social! | |||
| Valerie Speirs on biomarkers in male breast cancer | 30 janv. 2023 | 00:17:40 | |
Prof Valerie Speirs (University of Aberdeen, Aberdeen, Scotland) discusses her Systematic Review on genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers in male breast cancer. Tell us what you thought about this episode Continue this conversation on social! | |||
| Sameer Bakhshi on sex disparities in childhood cancer in India | 03 janv. 2023 | 00:23:02 | |
Prof Sameer Bakhshi, (All India Institute of Medical Sciences, New Delhi, India) discusses his Article on sex disparities in childhood cancer in India. Tell us what you thought about this episode Continue this conversation on social! | |||
| Shankar Siva on radiotherapy for primary renal cell carcinoma | 28 nov. 2022 | 00:08:30 | |
Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma. Tell us what you thought about this episode Continue this conversation on social! | |||
| Mark Lawler and Richard Sullivan on the European Groundshot | 15 nov. 2022 | 00:23:20 | |
Mark Lawler (Queen’s University Belfast, Belfast, UK) and Richard Sullivan (Kings College London, London, UK) discuss the European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission. Tell us what you thought about this episode Continue this conversation on social! | |||
| Samar Alhomoud on challenges for cancer control in the Gulf region | 31 oct. 2022 | 00:11:27 | |
Samar Alhomoud (King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia) discusses her review on progress and remaining challenges for cancer control in the Gulf Cooperation Council. Tell us what you thought about this episode Continue this conversation on social! | |||
| Inge Marie Svane on mRNA vaccines for cancer treatment | 27 sept. 2022 | 00:08:11 | |
Inge Marie Svane (Copenhagen University Hospital, Copenhagen, Denmark) discusses her Review on clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Tell us what you thought about this episode Continue this conversation on social! | |||